JP2014501492A5 - - Google Patents

Download PDF

Info

Publication number
JP2014501492A5
JP2014501492A5 JP2013532277A JP2013532277A JP2014501492A5 JP 2014501492 A5 JP2014501492 A5 JP 2014501492A5 JP 2013532277 A JP2013532277 A JP 2013532277A JP 2013532277 A JP2013532277 A JP 2013532277A JP 2014501492 A5 JP2014501492 A5 JP 2014501492A5
Authority
JP
Japan
Prior art keywords
short rna
strand
rna
short
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013532277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014501492A (ja
JP5681955B2 (ja
Filing date
Publication date
Priority claimed from GBGB1016989.4A external-priority patent/GB201016989D0/en
Priority claimed from GBGB1103745.4A external-priority patent/GB201103745D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/051940 external-priority patent/WO2012046084A2/en
Publication of JP2014501492A publication Critical patent/JP2014501492A/ja
Publication of JP2014501492A5 publication Critical patent/JP2014501492A5/ja
Application granted granted Critical
Publication of JP5681955B2 publication Critical patent/JP5681955B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013532277A 2010-10-08 2011-10-10 短いｒｎａ分子 Expired - Fee Related JP5681955B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1016989.4 2010-10-08
GBGB1016989.4A GB201016989D0 (en) 2010-10-08 2010-10-08 Cell induction
GBGB1103745.4A GB201103745D0 (en) 2011-03-07 2011-03-07 Cell induction
GB1103745.4 2011-03-07
PCT/GB2011/051940 WO2012046084A2 (en) 2010-10-08 2011-10-10 Short rna molecules

Publications (3)

Publication Number Publication Date
JP2014501492A JP2014501492A (ja) 2014-01-23
JP2014501492A5 true JP2014501492A5 (enExample) 2014-11-13
JP5681955B2 JP5681955B2 (ja) 2015-03-11

Family

ID=44860439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013532277A Expired - Fee Related JP5681955B2 (ja) 2010-10-08 2011-10-10 短いｒｎａ分子

Country Status (8)

Country Link
US (6) US8835400B2 (enExample)
EP (2) EP2625272B1 (enExample)
JP (1) JP5681955B2 (enExample)
KR (1) KR20130132795A (enExample)
CN (1) CN103314108B (enExample)
AU (1) AU2011311344B2 (enExample)
CA (1) CA2817191A1 (enExample)
WO (2) WO2012046084A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130132795A (ko) 2010-10-08 2013-12-05 미나 테라퓨틱스 리미티드 짧은 rna 분자
WO2014022455A1 (en) 2012-07-31 2014-02-06 The Board Of Regents Of The University Of Texas System Methods and compositions for in vivo induction of pancreatic beta cell formation
CA3236835A1 (en) 2013-11-22 2015-05-28 Mina Therapeutics Limited C/ebp alpha short activating rna compositions and methods of use
US20170044540A1 (en) * 2014-04-22 2017-02-16 Mina Therapeutics Limited Sarna compositions and methods of use
US20180305689A1 (en) * 2015-04-22 2018-10-25 Mina Therapeutics Limited Sarna compositions and methods of use
CN106480028B (zh) * 2016-10-12 2019-04-05 上海市第七人民医院 TPO基因的saRNA分子及其应用
WO2018237170A1 (en) * 2017-06-21 2018-12-27 Bertram Timothy A BIOACTIVE IMMUNO-PRIVILEGE RENAL CELLS FOR THE TREATMENT OF RENAL DISEASE
KR102007457B1 (ko) 2017-06-30 2019-08-05 동국대학교 산학협력단 Cas9 단백질, 가이드 RNA 및 양친매성 펩타이드를 포함하는 나노복합체 및 이의 용도
US11427826B2 (en) * 2017-08-11 2022-08-30 City of Hopw RNA aptamers against transferrin receptor (TfR)
EP4219715A3 (en) 2017-09-08 2023-09-06 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
CA3075205A1 (en) 2017-09-08 2019-03-14 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
CA3094575A1 (en) * 2018-04-10 2019-10-17 Ractigen Therapeutics Novel small activating rna
WO2019217571A1 (en) * 2018-05-08 2019-11-14 University Of Miami Materials and methods for the delivery of therapeutic nucleic acids to tissues
US20210254069A1 (en) 2018-06-15 2021-08-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
CN111849968A (zh) 2019-04-30 2020-10-30 中美瑞康核酸技术(南通)研究院有限公司 寡核苷酸分子及其在急性间歇性卟啉症治疗中的应用
EP4017539A1 (en) 2019-08-19 2022-06-29 MiNA Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
EP4329777A1 (en) 2021-04-28 2024-03-06 MiNA Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US8193330B2 (en) 1999-04-06 2012-06-05 The Regents Of The University Of California Polynucleotides comprising Neurogenin3 promoter and bHLH encoding domains
ATE450621T2 (de) 2000-03-30 2009-12-15 Whitehead Biomedical Inst Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind
GB0329449D0 (en) 2003-12-19 2004-01-28 Omnicyte Ltd Stem cells
JP5362350B2 (ja) * 2005-04-15 2013-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 小分子活性化ｒｎａ分子及び使用方法
US8357666B2 (en) 2005-08-01 2013-01-22 Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through RNA interference
EP2641970B1 (en) 2005-11-17 2014-12-24 Board of Regents, The University of Texas System Modulation of gene expression by oligomers targeted to chromosomal DNA
JP5713377B2 (ja) 2005-12-28 2015-05-07 ザ スクリプス リサーチ インスティテュート 薬物標的としての天然アンチセンスおよび非コードｒｎａ転写物
WO2008109449A1 (en) * 2007-03-02 2008-09-12 Mdrna Inc. Nucleic acid compounds for inhibiting bcl2 gene expression and uses thereof
WO2008109556A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting telomerase gene expression and uses thereof
PT2164993T (pt) 2007-05-29 2017-01-12 Reid Christopher B Métodos para produção e usos de populações de células multipotentes, populações de células pluripotentes, populações de célula diferenciadas e populações de células resistentes a vih
WO2009046397A2 (en) 2007-10-04 2009-04-09 Board Of Regents, The University Of Texas System Modulating gene expression with agrna and gapmers targeting antisense transcripts
JP2011507554A (ja) 2007-12-28 2011-03-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 遺伝子発現を増加させるための方法および組成物
EP2276838A4 (en) 2008-04-07 2012-02-01 Nupotential Inc RE-PROGRAMMING A CELL BY INDUCING A PLURIPOTENTIC GENE THROUGH RNA INTERFERENCE
WO2009126927A2 (en) 2008-04-11 2009-10-15 Joslin Diabetes Center, Inc. Methods of generating insulin-producing cells
WO2010047216A1 (ja) 2008-10-23 2010-04-29 国立大学法人 東京大学 microRNAの機能阻害法
JP2012508585A (ja) 2008-11-13 2012-04-12 ベイラー リサーチ インスティテュート インビボにおいて送達される膵島転写因子遺伝子による膵島の再生及び糖尿病の回復
US20120207744A1 (en) * 2009-03-19 2012-08-16 Mendlein John D Reprogramming compositions and methods of using the same
WO2010135329A2 (en) 2009-05-18 2010-11-25 Curna, Inc. Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
ES2693088T3 (es) 2009-07-20 2018-12-07 Janssen Biotech, Inc. Diferenciación de células madre embriónicas humanas
CN102822342B (zh) * 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
GB201010557D0 (en) 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
US8635602B2 (en) 2010-07-26 2014-01-21 International Business Machines Corporation Verification of information-flow downgraders
KR20130132795A (ko) * 2010-10-08 2013-12-05 미나 테라퓨틱스 리미티드 짧은 rna 분자

Similar Documents

Publication Publication Date Title
MX359548B (es) Agentes de iarn modificados.
MX2020011807A (es) Composiciones y metodos para inhibir la expresion genica del virus de hepatitis b.
WO2014022739A3 (en) Modified rnai agents
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
MX2013005110A (es) Inhibidores del ibat para el tratamiento de padecimientos metabolicos y condiciones relacionadas.
EA200870366A1 (ru) Короткая внутренне сегментированная интерферирующая рнк
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112015013809A2 (pt) derivados de exendina-4 como agonistas duplos de glp1/gip ou trigonais de glp1/gip/lucagon, seu uso e composição farmacêutica
JP2012041342A5 (enExample)
EA200802247A1 (ru) Схема дозирования кладрибина для лечения рассеянного склероза
BR112012018116A2 (pt) "hormônios do crescimento com eficácia in vivo prolongada"
JP2014500249A5 (enExample)
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
HK1200274A1 (en) Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
JP2015514778A5 (enExample)
UY32444A (es) Composiciones y procedimientos para terapia extendida con aminopiridinas
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
BR112014002173A2 (pt) proteínas purificadas
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
PH12014502802B1 (en) Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient
MX368184B (es) Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación.
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
MX348555B (es) Agente preventivo o terapeutico contra la fibrosis.
SG143203A1 (en) Use of agomelatine in obtaining medicaments intended for the treatment of smith-magenis syndrome
EA201290485A1 (ru) Производные бензамида